Kazuma Ohyashiki

20.7k total citations · 2 hit papers
471 papers, 13.7k citations indexed

About

Kazuma Ohyashiki is a scholar working on Hematology, Molecular Biology and Genetics. According to data from OpenAlex, Kazuma Ohyashiki has authored 471 papers receiving a total of 13.7k indexed citations (citations by other indexed papers that have themselves been cited), including 276 papers in Hematology, 155 papers in Molecular Biology and 141 papers in Genetics. Recurrent topics in Kazuma Ohyashiki's work include Acute Myeloid Leukemia Research (146 papers), Chronic Myeloid Leukemia Treatments (138 papers) and Chronic Lymphocytic Leukemia Research (94 papers). Kazuma Ohyashiki is often cited by papers focused on Acute Myeloid Leukemia Research (146 papers), Chronic Myeloid Leukemia Treatments (138 papers) and Chronic Lymphocytic Leukemia Research (94 papers). Kazuma Ohyashiki collaborates with scholars based in Japan, United States and Taiwan. Kazuma Ohyashiki's co-authors include Junko H. Ohyashiki, Keisuke Toyama, Tomohiro Umezu, Tetsuzo Tauchi, Miguel Á. Sanz, Michelle M. LeBeau, Pierre Morel, John M. Bennett, Pierre Fenaux and Ghulam Mufti and has published in prestigious journals such as Journal of Biological Chemistry, Nature Communications and Nature Genetics.

In The Last Decade

Kazuma Ohyashiki

456 papers receiving 13.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

International Scoring System for Evaluating Prognosis in Myelodysplastic Syndromes

1997 3.2k citations Kazuma Ohyashiki, Keisuke Toyama et al. Blood profile →
Exosomal miR-135b shed from hypoxic multiple myeloma cells enhances angiogenesis by targeting factor-inhibiting HIF-1

2014 508 citations Kazuma Ohyashiki, Junko H. Ohyashiki et al. Blood profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Kazuma Ohyashiki Japan	46	7.0k	6.3k	3.2k	2.1k	1.8k	471	13.7k
Kevin Shannon United States	58	3.7k 0.5×	6.2k 1.0×	1.7k 0.5×	871 0.4×	2.2k 1.2×	276	12.5k
Michael Lübbert Germany	60	7.2k 1.0×	7.4k 1.2×	2.2k 0.7×	1.1k 0.5×	2.0k 1.1×	297	12.7k
Nicholas C.P. Cross United Kingdom	75	11.5k 1.6×	7.1k 1.1×	8.5k 2.7×	1.3k 0.6×	2.2k 1.2×	395	19.9k
Claus R. Bartram Germany	48	4.1k 0.6×	3.8k 0.6×	2.1k 0.7×	1.3k 0.6×	1.7k 1.0×	212	10.0k
Carlos E. Bueso‐Ramos United States	59	6.0k 0.9×	5.8k 0.9×	4.3k 1.4×	2.4k 1.1×	3.0k 1.7×	386	14.7k
Tomoki Naoe Japan	56	7.9k 1.1×	8.1k 1.3×	2.7k 0.9×	2.9k 1.4×	2.9k 1.6×	352	15.9k
Yuzuru Kanakura Japan	58	4.7k 0.7×	4.6k 0.7×	2.3k 0.7×	854 0.4×	3.4k 1.9×	368	16.5k
Oliver G. Ottmann Germany	62	10.4k 1.5×	4.9k 0.8×	5.0k 1.6×	748 0.4×	4.0k 2.2×	372	16.1k
Alan F. List United States	68	15.4k 2.2×	8.3k 1.3×	6.5k 2.1×	1.2k 0.6×	4.2k 2.4×	621	21.9k
Wolfram Ruf United States	70	9.1k 1.3×	4.0k 0.6×	3.5k 1.1×	2.2k 1.0×	1.3k 0.7×	280	15.7k

Countries citing papers authored by Kazuma Ohyashiki

Since Specialization

Citations

This map shows the geographic impact of Kazuma Ohyashiki's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kazuma Ohyashiki with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kazuma Ohyashiki more than expected).

Fields of papers citing papers by Kazuma Ohyashiki

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kazuma Ohyashiki. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kazuma Ohyashiki. The network helps show where Kazuma Ohyashiki may publish in the future.

Co-authorship network of co-authors of Kazuma Ohyashiki

This figure shows the co-authorship network connecting the top 25 collaborators of Kazuma Ohyashiki. A scholar is included among the top collaborators of Kazuma Ohyashiki based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kazuma Ohyashiki. Kazuma Ohyashiki is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Yokomizo‐Nakano, Takako, Sho Kubota, Jie Bai, et al.. (2020). Overexpression of RUNX3 Represses RUNX1 to Drive Transformation of Myelodysplastic Syndrome. Cancer Research. 80(12). 2523–2536. 14 indexed citations

Katagiri, Seiichiro, Daigo Akahane, Hiroaki Fujimoto, et al.. (2018). Cardiac biopsy with intracardiac echocardiographic guidance for successful diagnosis of cardiac lymphoma. Clinical Case Reports. 6(9). 1681–1683. 5 indexed citations

Najima, Yuho, Chikashi Yoshida, Noriyoshi Iriyama, et al.. (2018). Regulatory T cell inhibition by dasatinib is associated with natural killer cell differentiation and a favorable molecular response—The final results of the D-first study. Leukemia Research. 66. 66–72. 29 indexed citations

Okabe, Seiichi, Yuko Tanaka, Tetsuzo Tauchi, & Kazuma Ohyashiki. (2018). Copanlisib, a novel phosphoinositide 3-kinase inhibitor, combined with carfilzomib inhibits multiple myeloma cell proliferation. Annals of Hematology. 98(3). 723–733. 15 indexed citations

Okabe, Seiichi, Tetsuzo Tauchi, Yuko Tanaka, & Kazuma Ohyashiki. (2017). Peroxisome Proliferator-Activated Receptors: Targets for the Treatment of Philadelphia Chromosome-Positive Leukemia Cells. Blood. 130. 5241–5241. 1 indexed citations

Tauchi, Tetsuzo, Seiichi Okabe, Seiichiro Katagiri, Yuko Tanaka, & Kazuma Ohyashiki. (2017). Combining Effects of the SMO Inhibitor and BCL-2 Inhibitor in MDS-Derived Induced Potent Stem Cells (iPSC). Blood. 130. 1249–1249. 3 indexed citations

Ogura, Michinori, Ken Ohmachi, Ritsuro Suzuki, et al.. (2017). A Phase II Study of THP-COP (pirarubicin, cyclophosphamide, vincristine and prednisolone) in Patients with Newly Diagnosed Advanced Peripheral T-Cell Lymphoma: THP-3 Study of Japan Hematopoietic Malignancy Clinical Study Group (HMCSG). Blood. 130. 2789–2789. 1 indexed citations

Katagiri, Seiichiro, Tetsuzo Tauchi, Seiichi Okabe, et al.. (2013). Combination of Ponatinib with Hedgehog Antagonist Vismodegib for Therapy-Resistant BCR-ABL1–Positive Leukemia. Clinical Cancer Research. 19(6). 1422–1432. 35 indexed citations

Okabe, Seiichi, Tetsuzo Tauchi, Yuko Tanaka, Seiichiro Katagiri, & Kazuma Ohyashiki. (2012). Effects of the Hedgehog Inhibitor GDC-0449, Alone or in Combination with Dasatinib, on BCR-ABL-Positive Leukemia Cells. Stem Cells and Development. 21(16). 2939–2948. 16 indexed citations

10.

Akiyama, Nobu, Keisuke Miyazawa, Yoshinobu Kanda, et al.. (2010). Multicenter phase II trial of vitamin K2 monotherapy and vitamin K2 plus 1α-hydroxyvitamin D3 combination therapy for low-risk myelodysplastic syndromes. Leukemia Research. 34(9). 1151–1157. 17 indexed citations

11.

Tanaka, Masami, Kosuke Oikawa, Masakatsu Takanashi, et al.. (2009). Down-Regulation of miR-92 in Human Plasma Is a Novel Marker for Acute Leukemia Patients. PLoS ONE. 4(5). e5532–e5532. 257 indexed citations

12.

Ohyashiki, Kazuma, Atsushi Kodama, & Junko H. Ohyashiki. (2008). Recurrent der(9;18) in essential thrombocythemia with JAK2 V617F is highly linked to myelofibrosis development. Cancer Genetics and Cytogenetics. 186(1). 6–11. 4 indexed citations

13.

Okabe, Seiichi, Tetsuzo Tauchi, Akihiro Nakajima, et al.. (2007). Depsipeptide (FK228) Preferentially Induces Apoptosis in BCR/ABL-Expressing Cell Lines and Cells from Patients with Chronic Myelogenous Leukemia in Blast Crisis. Stem Cells and Development. 16(3). 503–514. 29 indexed citations

14.

Tauchi, Tetsuzo & Kazuma Ohyashiki. (2004). Imatinib Mesylate in Combination with Other Chemotherapeutic Agents for Chronic Myelogenous Leukemia. International Journal of Hematology. 79(5). 434–440. 6 indexed citations

15.

Ikebuchi, Kenji, Hirofumi Hamada, Yoshiro Niitsu, et al.. (2003). Changes in N-glycosylation of human stromal cells by telomerase expression. Biochemical and Biophysical Research Communications. 301(2). 293–297. 11 indexed citations

16.

Kawanishi, Y, Kazuya Ando, Hiroshi Iwama, et al.. (2000). [Rapidly progressive fibrosis and increased CD68-positive cells in the bone marrow at the terminal stage of adult T-cell leukemia accompanied by polycythemia vera].. PubMed. 41(12). 1254–9. 2 indexed citations

17.

Shimamoto, Takashi, et al.. (1995). [The expression pattern of transcription factors (GATA, SCL) and biological characteristics in various leukemia cells].. PubMed. 36(6). 547–51. 3 indexed citations

18.

Ohyashiki, Kazuma, Junko H. Ohyashiki, Ken Kawakubo, et al.. (1994). Telomere shortening in leukemic cells is related to their genetic alterations but not replicative capability. Cancer Genetics and Cytogenetics. 78(1). 64–67. 25 indexed citations

19.

Kubonishi, Ichiro, Taisuke Eguchi, Shoki Yano, et al.. (1992). Establishment of a new Hodgkin's cell line (HD-70) of B-cell origin. Cancer. 69(4). 1034–1041. 13 indexed citations

20.

Ohyashiki, Kazuma, Junko H. Ohyashiki, Keisuke Toyama, et al.. (1990). Cytogenetic findings in adult acute leukemia and myeloproliferative disorders with an involvement of megakaryocyte lineage. Cancer. 65(4). 940–948. 21 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact